期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
高分子抗肿瘤纳米药物的挑战与发展 被引量:12
1
作者 孙瑞 邱娜莎 申有青 《高分子学报》 SCIE CAS CSCD 北大核心 2019年第6期588-601,共14页
抗肿瘤纳米药物的理想目标是降低毒副作用并提高疗效,但目前临床用纳米药物主要以显著降低药物毒性的优势获批进入临床.近年来,肿瘤分子靶向治疗、免疫治疗等高疗效方法的飞速发展,使提高疗效成为抗肿瘤纳米药物研究的当务之急.静脉注... 抗肿瘤纳米药物的理想目标是降低毒副作用并提高疗效,但目前临床用纳米药物主要以显著降低药物毒性的优势获批进入临床.近年来,肿瘤分子靶向治疗、免疫治疗等高疗效方法的飞速发展,使提高疗效成为抗肿瘤纳米药物研究的当务之急.静脉注射的纳米药物向实体肿瘤靶向输送过程是血液系统内循环、从血管外渗进入肿瘤组织和蓄积、肿瘤组织内渗透、肿瘤细胞内吞、胞内药物释放的五步'级联'递送过程(即CAPIR cascade).因此,如何设计载体高分子的功能,赋予纳米药物随血液系统、肿瘤组织和肿瘤细胞的微环境的变化而改变其纳米尺寸(size)、表面(surface)和稳定性(stability)(即3S nanoproperty transitions),从而满足肿瘤靶向输送过程中各步的要求以确保每一步具有高的效率,是获得高肿瘤靶向输送效率和高疗效的关键.本文将介绍利用各种响应高分子包括作者提出的电荷反转型高分子来设计具有上述3S纳米特性转换能力的高效纳米药物的方法,并总结了今后高分子纳米药物研究面临的挑战和发展趋势. 展开更多
关键词 纳米药物 功能高分子 肿瘤靶向输送 纳米特转换 治疗性高分子 分子纳米药物
原文传递
Therapeutic Activity of Partially Purified Fractions of Emblica officinalis (Syn, Phyllanthus embfica) Dried Fruits against Trypanosoma evansi
2
作者 Shaba Peter Sahab Dey +2 位作者 Bhanuprakash Veerakyathappa Singh Raj Kumar Chaudary Paulad 《Journal of Pharmacy and Pharmacology》 2016年第10期546-558,共13页
Emblica officinalis (E. oJficinalis) dried fruits were evaluated for its antitrypanosomal activity and cytotoxic effects. Vero cell line maintained in DMEM (Dubecco's Modified Eagle Medium) and incubated with Try... Emblica officinalis (E. oJficinalis) dried fruits were evaluated for its antitrypanosomal activity and cytotoxic effects. Vero cell line maintained in DMEM (Dubecco's Modified Eagle Medium) and incubated with Trypanosoma evansi for more than 12 h. MPE was added to the Vero cell culture medium at different concentrations (250-1,000 μg/mL) with trypanosomes concentration (1 × 106 trypanosomes/mL in each ELISA plate well) and incubated at appropriate conditions for 72 h. In-vitro cytotoxieity of MPE of E. officinalis was determined on Vero cells at concentrations ((1.56-100 ~tg/mL). Acute toxicity and in-vivo infectivity tests were done in mice. Obtained MPE ofE. officinalis underwent process of purification via column chromatography, preparative chromatography and HPLC (higher performance liquid chromatography) with bioassay at different strata on Alsever's medium. In-vivo assay for trypanocidal activity, MPE and PPFs (partially purified fractions) of E. officinalis with two sets of mice, each mouse was inoculated with 1 × 104/mL oftrypanosomes and treated (48 h post inoculation) at concentrations (12.5, 25, 50, 100 and 200 mg/kg body weight) were administered at dose rate of 100 [tL per mouse via intraperitoneal route (in treating parassitemic mice) to different groups of mice, 6 mice per concentration. HPLC of partially purified fractions ofE. officinalis was carried out with mobile phase ofacetonitdle: water (40:60) in gradient mode. In vitro, MPE induced immobilization and killing of the parasites in concentration-time dependent manner. Significant reduction of trypanosomes counts from concentration of 250μg/mL and complete killing of trypanosomes at 5th hour of observation, which was statistically equivalent to 4th hour of Diminazine Aceturate (Berenil), standard reference drug used. HPLC of the partially purified fractions revealed two major prominent peaks at retention time of 1-4 min. In vivo, both MPE and PPFs of test material did prolong lives of mice by 6-9 days but could not cure them. At concentration of 2,000 kg/kg body weight of MPE in acute test, all mice survived. For in-vivo infectivity test, mice injected with immobilized trypanosomes developed parasitemia and died while, the other group survived. MPE, PPFs and Diminazine Aceturate were toxic to Vero cells at all concentrations exception of 1.56, 1.56-3.13 and 1.56-6.25 μg/mL, respectively. From this report, PPFs ofE. officinalis dried fruits demonstrated potential pathway for a new development oftrypanocide in near future if additional investigations are put in place. 展开更多
关键词 Emblica officinalis dried fruits in vitro and in vivo partially purified fractions trypanocidal activity Trypanosoma evansi in vitro cytotoxicity.
下载PDF
抗肿瘤纳米药物的设计与挑战 被引量:7
3
作者 刘婧 胡豆豆 +1 位作者 周泉 申有青 《中国科学:化学》 CAS CSCD 北大核心 2019年第9期1192-1202,共11页
抗肿瘤纳米药物因能缓解传统小分子化疗药的全身毒性而进入临床应用.但目前研究的多数抗肿瘤纳米药物未能显著提高肿瘤治疗效果,因而止步于临床前或早期临床研究,如何显著提高疗效已成为下一代抗肿瘤纳米药物亟需解决的关键问题.分析体... 抗肿瘤纳米药物因能缓解传统小分子化疗药的全身毒性而进入临床应用.但目前研究的多数抗肿瘤纳米药物未能显著提高肿瘤治疗效果,因而止步于临床前或早期临床研究,如何显著提高疗效已成为下一代抗肿瘤纳米药物亟需解决的关键问题.分析体内肿瘤靶向过程可知,静脉注射的纳米药物需经过体内血液循环(C)、肿瘤蓄积(A)、肿瘤内渗透(P)、被细胞内吞(I)和在胞内释放(R)五步级联过程(即CAPIR cascade)才能在肿瘤细胞内发挥药效.使纳米药物的纳米特性包括稳定性(stability)、表面性质(surface properties)、尺寸(size)随输送过程各步的要求自主适应(self-adaptive)是纳米药物高效完成输送过程、获得高疗效的关键,但在肿瘤组织中渗透能力的天然缺失仍是纳米药物的"短板".在临床转化方面,体内安全性评价的复杂性和可控生产的复杂性是功能集成型纳米药物临床转化的瓶颈.同时,本文还介绍了我们最近提出的基于剥夺肿瘤信号分子的铜元素、使信号蛋白失活而达到抑瘤效果的新型类分子靶向药物. 展开更多
关键词 纳米药物 临床转化 肿瘤渗透 治疗性高分子 树枝状大分子
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部